The Medical Letter on Drugs and Therapeutics
Empagliflozin (Jardiance) for Type 2 Diabetes in Children (online only)
Download PDF:   US English
Med Lett Drugs Ther. 2023 Aug 21;65(1683):e137   doi:10.58347/tml.2023.1683e
Principal Faculty
  • Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
  • Brinda M. Shah, Pharm.D., Consulting Editor has disclosed no relevant financial relationships.
Upon completion of this activity, the participant will be able to:
  1. Review the efficacy and safety of empagliflozin (Jardiance) for type 2 diabetes in children.
 Select a term to see related articles  Bydureon BCise   empagliflozin   exenatide   Jardiance   liraglutide   metformin   Synjardy   type 2 diabetes   Victoza 

The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin has been available for years alone (Jardiance – Boehringer Ingelheim) and in combination with metformin (Synjardy) to improve glycemic control in adults with type 2 diabetes. Both products have now been approved for use in children ≥10 years old. Empagliflozin is the second oral drug to become available in the US for treatment of type 2 diabetes in children; metformin has been available since 2000 for this indication. The injectable glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide (Victoza) and extended-release exenatide (Bydureon BCise) are also approved for use in children ≥10 years old.1

MECHANISM OF ACTION ― SGLT2 inhibitors decrease renal glucose reabsorption and increase urinary glucose excretion, reducing fasting and postprandial blood glucose levels.

CLINICAL STUDIES ― FDA approval of the expanded indication was based on the results of a double-blind trial (DINAMO) in 158 patients 10-17 years old with an A1C of 6.5-10.5% who were randomized to receive empagliflozin, the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (off-label), or placebo once daily. Most patients in the trial were also taking metformin and/or insulin. At week 26, the mean change from baseline in A1C was -0.17% with empagliflozin, +0.33% with linagliptin, and +0.68% with placebo; the difference between empagliflozin and placebo was statistically significant. Compared to placebo, there was a mean weight loss of 0.75 kg with empagliflozin and a weight gain of 1.46 kg with linagliptin.2

ADVERSE EFFECTS ― Adverse effects of SGLT2 inhibitors include genital mycotic infections, urinary tract infections, and volume depletion, which can lead to hypotension and acute kidney injury. Empagliflozin has been associated with ketoacidosis in patients with type 1 diabetes and in some insulin-deficient patients with type 2 diabetes.

DOSAGE, ADMINISTRATION, AND COST ― Jardiance is available in 10- and 25-mg tablets. The recommended starting dosage for treatment of type 2 diabetes in patients of any age is 10 mg once daily; the dose can be increased to 25 mg as needed. Synjardy, which is available in tablets containing 5 or 12.5 mg of empagliflozin and either 500 or 1000 mg of metformin, is taken twice daily. The maximum daily dose is 25 mg/2000 mg. The wholesale acquisition cost for a 30-day supply of Jardiance or Synjardy is $593.30.3

CONCLUSION ― Addition of the oral SGLT2 inhibitor empagliflozin (Jardiance) to metformin and/or insulin reduced A1C in one small trial in patients 10-17 years old with type 2 diabetes.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article